Premium
Human papillomavirus testing using hybrid capture II with surepath collection
Author(s) -
Ko Vincent,
Tambouret Rosemary H.,
Kuebler Diane L.,
BlackSchaffer W. Stephen,
Wilbur David C.
Publication year - 2006
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22285
Subject(s) - medicine , squamous intraepithelial lesion , human papillomavirus , cervical intraepithelial neoplasia , cytology , biopsy , food and drug administration , gynecology , hybrid capture , oncology , cervical cancer , pathology , cancer , environmental health
BACKGROUND. Testing for human papillomavirus (HPV) is an integral part of equivocal cervical cytology triage. Clinical validation of non‐FDA (Food and Drug Administration)–approved methods is therefore important because of the high volume of such tests and the implications for missed high‐grade lesions if test performance is not optimal. METHODS. A preinitiation study and 17 months of follow‐up data using Hybrid Capture II (HC II) HPV detection with SurePath (SP) sample collection were analyzed. Results of HPV tests on abnormal cytology samples were collected and compared with follow‐up results. HPV‐positive rates were determined in cases of low‐grade squamous intraepithelial lesion (LSIL) and high‐grade squamous intraepithelial lesion (HSIL), and follow‐up rates of cervical intraepithelial neoplasia (CIN) were determined in HPV‐positive and ‐negative cases of atypical squamous cells of unknown significance (ASC‐US). Rates were compared with published data using FDA‐validated methods. RESULTS. The preinitiation study showed the test method to be 100% sensitive for the detection of LSIL (20 cases) and HSIL (8). The ASC‐US follow‐up study (2319 cases with 625 having biopsy results) showed that the rate of CIN III+ in HPV +/− cases was 7.8%/1.4%, and of CIN II+ was 17.5%/4.3%, respectively. The positive predictive values/negative predictive values (PPV/NPVs) (CIN II+) for the test were 17.5%/95.7%, respectively. CONCLUSIONS. Published FDA‐validated HPV testing follow‐up data show that the expected rates of CIN III+ and CIN II+ in the HPV‐negative ASC‐US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively. By comparison, the present data using HC II with SP show strong similarity, indicating clinical validity for the use of this method. Cancer (Cancer Cytopathol) 2006; © 2006 American Cancer Society.